11:44 AM EST - Aralez Pharmaceuticals Inc : Has resubmitted to the U.S. Food and Drug Administration the New Drug Application for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. Aralez Pharmaceuticals Inc
shares T.ARZ are trading down $1.40 at $6.50.
